DC-15442 is a potent small molecule STAT6 inhibitor, which is not a degrader or prodrug, being advanced as a safe dupilumab-in-a-pill alternative for patients BOSTON, June 10, 2025 /PRNewswire ...

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more ...

Dupilumab (Sanofi) cemented its position as the top-selling inflammatory illness medication with its first-in-class IL-4Rα antagonist. In 2024, it generated $14.179 billion in sales (23% YoY growth).

Glycosylation is the reaction catalysed by glycosyltransferases, which adds carbohydrates site-specifically to another molecule, generally proteins and lipids. Glycosylation comes in five forms: N ...

Results support commitment to enhance clinical understanding of chronic diseases in communities of color. TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

In the trial, Dupixent ® (dupilumab) outperformed Xolair ® (omalizumab) on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints. The data are from the first-ever ...

In the study, Dupixent (dupilumab) outperformed Xolair (omalizumab) on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints. The data are from the first-ever ...

Dupilumab, which is taken by more than one million patients, is approved for both eczema and asthma, among other conditions. The treatment is an antibody administered as an injectable biologic ...

Regeneron Contacts: Media Relations Anna Hodge Tel: +1 914-255-6475 [email protected] Sanofi Contacts: Media Relations Sandrine Guendoul Tel: +33 6 25 09 14 25 ...

SAN FRANCISCO — Hyperpolarized xenon MRI may be useful in assessing response to biologic treatment among patients with asthma, according to a poster presented at the American Thoracic Society ...

The aim is to prepare for the onset of biosimilar competition in the 2030s to Sanofi’s current immunology blockbuster Dupixent (dupilumab), which is predicted to top $14 billion in sales this ...